A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC)

被引：1
|
作者：
Moreno, V. [1 ]
Bauer, T. M. [2 ]
Infante, J. [3 ]
Govindan, R. [4 ]
Besse, B. [5 ]
Bertino, E. [6 ]
Martinez Marti, A. [7 ]
Piontek, T. [8 ]
Dhar, A. [9 ]
机构：
[1] Fdn Jimenez Diaz Hosp, START Madrid FJD, Med Oncol, Madrid, Spain
[2] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[3] Sarah Cannon Res Inst, Other, Nashville, TN USA
[4] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA
[5] Inst Gustave Roussy, Dept Med, Villejuif, France
[6] Ohio State Univ, Med Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[7] Vall dHebron Univ Hosp, Inst Oncol, Med Oncol, Barcelona, Spain
[8] GlaxoSmithKline, RD Projects Clin Platforms & Sci, Collegeville, PA USA
[9] GlaxoSmithKline, Onocolgy R&D, Collegeville, PA USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
381P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
    Bauer, Todd M.
    Besse, Benjamin
    Martinez-Marti, Alex
    Trigo, Jose Manuel
    Moreno, Victor
    Garrido, Pilar
    Ferron-Brady, Geraldine
    Wu, Yuehui
    Park, Jennifer
    Collingwood, Therese
    Kruger, Ryan G.
    Mohammad, Helai P.
    Ballas, Marc S.
    Dhar, Arindam
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1828 - 1838
  • [2] Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
    Roboz, Gail J.
    Yee, Karen
    Verma, Amit
    Borthakur, Gautam
    de la Fuente Burguera, Adolfo
    Sanz, Guillermo
    Mohammad, Helai P.
    Kruger, Ryan G.
    Karpinich, Natalie O.
    Ferron-Brady, Geraldine
    Acusta, Andre
    Del Buono, Heather
    Collingwood, Therese
    Ballas, Marc
    Dhar, Arindam
    Wei, Andrew H.
    LEUKEMIA & LYMPHOMA, 2022, 63 (02) : 463 - 467
  • [3] Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).
    Volchek, Yulia
    Zimran, Eran
    Kirgner, Ilya
    Yin, Lina
    Yusuf, Rushdia
    Gumuscu, Burak
    Ross, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with polycythemia vera (PV).
    Rinaldi, Ciro
    Rein, Lindsay
    Livings, Alice
    Innes, Andrew J.
    Pettit, Kristen
    Yeh, Paul
    Larsen, Stephen R.
    Watson, Anne-Marie
    Leahy, Michael F.
    Curto-Garcia, Natalia
    Mahdi, Ali
    Frewin, Rebecca
    Qureshi, Haifz
    Shatzel, Joseph
    Vaughn, Jennifer
    Tashi, Tsewang
    Amin, Harshad
    Ogbu, Uzor
    Gumuscu, Burak
    Ross, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS
    Watts, Justin M.
    Bradley, Terrence J.
    Thomassen, Amber
    Dinh, Yvonne Trang
    Tejera, Dalissa
    Englund, Kristen
    Boga, Sorab
    Astaiza, Randy
    Chen, Charles J.
    Abdur-Rahman, Malika
    Ion, Marinescu
    Perez, Aymee
    Tayari, Masoumeh
    Morey, Lluis
    Figueroa, Maria E.
    Shiekhattar, Ramin
    Zelent, Arthur
    Swords, Ronan
    BLOOD, 2018, 132
  • [6] Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
    Hollebecque, Antoine
    Salvagni, Stefania
    Plummer, Ruth
    Isambert, Nicolas
    Niccoli, Patricia
    Capdevila, Jaume
    Curigliano, Giuseppe
    Moreno, Victor
    Martin-Romano, Patricia
    Baudin, Eric
    Arias, Marina
    Mora, Sheila
    de Alvaro, Juan
    Di Martino, Jorge
    Parra-Palau, Josep L.
    Sanchez-Perez, Tania
    Aronchik, Ida
    Filvaroff, Ellen H.
    Lamba, Manisha
    Nikolova, Zariana
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 438 - 446
  • [7] Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines
    Welch, Darcy
    Kahen, Elliot
    Fridley, Brooke
    Brohl, Andrew S.
    Cubitt, Christopher L.
    Reed, Damon R.
    PLOS ONE, 2019, 14 (09):
  • [8] An open-label, phase II study of the polo-like kinase-1 (P1k-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
    Awad, Mark M.
    Chu, Quincy S-C
    Gandhi, Leena
    Stephenson, Joe J.
    Govindan, Ramaswamy
    Bradford, Daniel S.
    Bonomi, Philip D.
    Ellison, David M.
    Eaton, Keith D.
    Fritsch, Holger
    Munzert, Gerd
    Johnson, Bruce E.
    Socinski, Mark A.
    LUNG CANCER, 2017, 104 : 126 - 130
  • [9] A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcoma.
    Reed, Damon R.
    Mascarenhas, Leo
    Meyers, Paul A.
    Chawla, Sant P.
    Harrison, Douglas James
    Setty, Bhuvana
    Metts, Jonathan
    Wages, David S.
    Stenehjem, David D.
    Santiesteban, Daniela Y.
    DuBois, Steven G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
    Krebs, Matthew G.
    Delord, Jean-Pierre
    Evans, Thomas R. Jeffry
    De Jonge, Maja
    Kim, Sang-We
    Meurer, Marie
    Postel-Vinay, Sophie
    Lee, Jong-Seok
    Angell, Helen K.
    Rocher-Ros, Vidalba
    Meyer, Kassondra
    Ah-See, Mei-Lin
    Herbolsheimer, Pia
    Lai, Zhongwu
    Nunes, Ana
    Domchek, Susan M.
    LUNG CANCER, 2023, 180
12345